Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$0.64 - $0.92 $43,036 - $61,865
67,245 New
67,245 $61,000
Q3 2023

Nov 14, 2023

SELL
$0.77 - $1.16 $128,677 - $193,851
-167,113 Reduced 74.87%
56,100 $52,000
Q2 2023

Aug 14, 2023

BUY
$1.01 - $1.42 $90,610 - $127,392
89,713 Added 67.2%
223,213 $252,000
Q1 2023

May 15, 2023

BUY
$0.75 - $1.98 $100,125 - $264,330
133,500 New
133,500 $169,000
Q2 2022

Aug 15, 2022

SELL
$0.43 - $0.91 $8,828 - $18,684
-20,532 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$0.67 - $1.39 $157,986 - $327,762
-235,800 Reduced 91.99%
20,532 $17,000
Q4 2021

Feb 14, 2022

SELL
$1.18 - $2.18 $138,067 - $255,073
-117,006 Reduced 31.34%
256,332 $326,000
Q3 2021

Nov 15, 2021

BUY
$1.48 - $2.35 $470,253 - $746,686
317,739 Added 571.48%
373,338 $836,000
Q2 2021

Aug 16, 2021

SELL
$1.87 - $2.7 $262,843 - $379,506
-140,558 Reduced 71.66%
55,599 $112,000
Q1 2021

May 17, 2021

BUY
$2.06 - $3.01 $260,416 - $380,512
126,416 Added 181.26%
196,157 $522,000
Q4 2020

Feb 16, 2021

BUY
$1.99 - $3.25 $10,978 - $17,930
5,517 Added 8.59%
69,741 $139,000
Q3 2020

Nov 16, 2020

SELL
$2.85 - $4.1 $471,495 - $678,291
-165,437 Reduced 72.04%
64,224 $183,000
Q2 2020

Aug 14, 2020

BUY
$2.39 - $4.0 $206,620 - $345,808
86,452 Added 60.37%
229,661 $847,000
Q1 2020

May 15, 2020

BUY
$1.74 - $4.26 $132,815 - $325,170
76,331 Added 114.13%
143,209 $355,000
Q4 2019

Feb 14, 2020

BUY
$1.77 - $3.84 $118,374 - $256,811
66,878 New
66,878 $257,000
Q2 2019

Aug 14, 2019

SELL
$1.49 - $2.94 $25,045 - $49,418
-16,809 Closed
0 $0
Q1 2019

May 15, 2019

SELL
$2.35 - $3.27 $29,469 - $41,005
-12,540 Reduced 42.73%
16,809 $45,000
Q4 2018

Feb 14, 2019

BUY
$2.1 - $4.5 $30,284 - $64,894
14,421 Added 96.6%
29,349 $69,000
Q3 2018

Nov 14, 2018

BUY
$3.7 - $5.25 $55,233 - $78,372
14,928 New
14,928 $66,000

About Cidara Therapeutics, Inc.


  • Ticker CDTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,075,696
  • Market Cap $1.24B
  • Description
  • Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifu...
More about CDTX
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.